<DOC>
	<DOC>NCT00773019</DOC>
	<brief_summary>This FDA Condition of Approval study will include up to 100 subjects at up to 13 US centers. Subjects are selected from those evaluated and planning to receive a SynchroMed II drug infusion system for treatment of severe spasticity or chronic pain. Subjects must return for refill visits at 1, 6, and 12 months. In addition, subjects return for any other medically necessary refills. Information is collected on all refills and adverse events.</brief_summary>
	<brief_title>SynchroMed II Post-Approval Study</brief_title>
	<detailed_description />
	<mesh_term>Chronic Pain</mesh_term>
	<criteria>Have chronic intractable severe spasticity or chronic pain requiring intrathecal delivery of medication Have undergone a preimplant assessment and determined to be an appropriate candidate for implantation of an infusion system Be geographically stable and willing to return to the study center for followup visits Subject, or subject's legal representative, has signed informed consent form prior to any studyrelated procedures Age is at least 18 years of age at time of enrollment Have a condition in which the pump cannot be implanted 2.5 cm or less from the surface of the skin Have an ongoing infection prior to implant Have insufficient body mass to accept the pump bulk and weight Are unable or unwilling to adhere to the study protocol Have an estimated life expectancy of less than twelve months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>infusion pump</keyword>
	<keyword>implantable</keyword>
	<keyword>performance</keyword>
</DOC>